| 摘要 |
<p>The invention relates to compounds of formula (I), wherein R1 and R3 have the meaning given in Claim 1. Said compounds are potent 5-HT2A-antagonists and are suitable for the treatment of psychosis, schizophrenia, depression, neurological disorders, memory disorders, Parkinson s disease, amyotrophic lateral sclerosis, Alzheimer s disease, Huntington s disease, eating disorders, e.g. nervous bulimia and anorexia, and premenstrual syndrome and/or for positively influencing compulsive behaviours (obsessive-compulsive disorder, OCD).</p> |
